Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders
Open accessThe DOI matches its Crossref record; 23 of the 26 references it cites were found in a registry or an index; 18 of the 33 sources its claims cite were checked for support.
Abstract
The 26S proteasome is a large, ATP-dependent proteolytic complex responsible for degrading ubiquitinated proteins in eukaryotic cells. It plays a crucial role in maintaining cellular protein homeostasis by selectively eliminating misfolded, damaged, or regulatory proteins marked for degradation. In this study, whole-exome sequencing (WES) was performed on an individual presenting with developmental delay and mild intellectual disability, as well as on both of his unaffected parents. This analysis identified a de novo variant, c.959C>G (p.Pro320Arg), in the PSMC5 gene. As predicted, this gene shows a very likely autosomal dominant inheritance pattern. Notably, PSMC5 has not previously been associated with any phenotype in the OMIM database. This variant was recently submitted to the ClinVar database as a variant of uncertain significance (VUS) and remains absent in both gnomAD and dbSNP. Notably, it has been identified in six unrelated individuals presenting with clinical features comparable to those observed in the patient described in this study. Multiple in silico prediction tools classified the variant as pathogenic, and a PhyloP conservation score supports strong evolutionary conservation of the mutated nucleotide. Protein structure predictions using the AlphaFold3 algorithm revealed notable structural differences between the mutant and wild-type PSMC5 proteins. We hypothesize that the p.Pro320Arg substitution alters the structure and function of PSMC5 as a regulatory subunit of the 26S proteasome, potentially impairing the stability and activity of the entire complex. Although functional studies are imperative, this study contributes to a deeper understanding of PSMC5, expands the spectrum of associated neurodevelopmental phenotypes, and highlights its potential as a therapeutic target. Furthermore, this study resulted in the submission of the identified variant to the ClinVar database (SCV006083352), where it was classified as pathogenic.
Overview
CoChat Summary
TL;DR
This case report used trio whole-exome sequencing to identify a de novo PSMC5 variant, c.959C>G (p.Pro320Arg), in a patient with global developmental delay and mild intellectual disability. In silico and AlphaFold3 analyses supported pathogenicity and predicted structural changes, but functional validation remains necessary.
Key findings
- WES identified a de novo heterozygous PSMC5 variant, c.959C>G (p.Pro320Arg), absent in both unaffected parents and in gnomAD and dbSNP; the patient was diagnosed with global developmental delay (HP:0001263) and mild intellectual disability (HP:0001256).
- The variant was classified as pathogenic by ACMG criteria, with a DOMINO autosomal dominant probability score of 0.981 and a PhyloP conservation score of 7.905; multiple in silico tools predicted pathogenic or strongly pathogenic effects (e.g., AlphaMissense 0.996, MetaRNN 0.977, REVEL 0.917).
- AlphaFold3 comparison of wild-type and mutant PSMC5 showed 251/406 residues aligned with RMSD 0.333 Å, but all 406 residues had RMSD 7.645 Å; wild-type had 339 hydrogen bonds versus 337 in the mutant, with 23 wild-type-only and 21 mutant-only hydrogen bonds. Wild-type Pro320 bonded with Arg325, while mutant Arg320 bonded with Arg325 and Thr194.
- The same p.Pro320Arg variant was previously identified in six unrelated individuals with neurodevelopmental disorders, including two DECIPHER de novo cases (IDs 306096 and 307251); PSMC5 was recently included in SFARI with a score of 3. The authors submitted the variant to ClinVar as SCV006083352, classified pathogenic.
Methods
- Trio whole-exome sequencing was performed on the patient and both parents using the Agilent SureSelect V7 kit and Illumina HiSeq 3000, achieving at least 20× coverage for 97% of targeted regions; variants were filtered by inheritance pattern and MAF <1%, aligned to HG38, and validated by Sanger sequencing.
- Variant classification used ACMG guidelines and VarSome; in silico prediction tools included BayesDel, MetaRNN, MetaSVM, REVEL, AlphaMissense, EIGEN, FATHMM-XF, Mutation assessor, MutPred, PrimateAI, PROVEAN, SIFT, and others.
- Structural analysis used AlphaFold3 predictions for wild-type and mutant PSMC5, selecting the best model by highest plDDT (wild-type model 3 average 81.125; mutant model 3 average 80.396), visualized with UCSF ChimeraX 1.8; BrainRNA-Seq, BrainSpan, and Complex Portal/PDB 6msk were also used.
Limitations
- The authors state that predicting the structural and functional consequences of Pro320Arg on the entire 26S proteasome is difficult; AlphaFold-Multimer analysis of the full complex was not performed because of the large number of subunits and computational resource requirements.
- The authors state that they cannot rule out other genetic variants not detected by WES that may have contributed to the patient’s clinical presentation, and that functional studies are imperative to confirm the gene–disease association and validate the variant as a potential mutational hotspot.
- The authors note that thyroid abnormalities were not reported in the six previously described individuals carrying the same variant, and they cannot conclusively attribute the patient’s thyroid abnormalities to the secondary FGFR1 variant c.2200C>T (p.Arg734Trp). Evident from the text: this is a single-patient case report with in silico structural predictions and no experimental functional validation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
14 Valid · 0 Not valid · 12 Not checked · 39 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Notably, the same p.Pro320Arg variant reported in this study was also identified in six individuals with neurodevelopmental disorders [12].”
- Also stated in: § Abstract · plain
“Notably, it has been identified in six unrelated individuals presenting with clinical features comparable to those observed in the patient described in this study.”
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > 3. Discussion
What the sources say
- Supportedcites [12] Yu, 2024, PSMC5 Insufficiency and P320R Mutation Impair Proteasome Function, Hum. Mol. Genet. source
The Results section (‘Identification of de novo PSMC5 variants—Case reports’; page not provided) reports two patients with p.P320R and four additional individuals carrying the same variant. It describes developmental delay and related neurodevelopmental difficulties in these individuals. (LLM, conf=0.94)
plainstates an associationn = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Among these, neurodevelopmental proteasomopathies have emerged as a complex group of syndromes caused by defects in genes related to key proteasome systems, such as the ubiquitin–proteasome system (UPS) and the previously mentioned 26S proteasome [5,6].”
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > 1. Introduction
What the sources say
- Supportedcites [5] Papendorf, J.J., Ebstein, F., Alehashemi, S., Piotto, D.G.P., Kozlova, A., Terreri, M.T., Shcherbina, A., Rastegar, A., Rodrigues, M., and Pereira, R. (2023). Identification of Eight Novel Proteasome Variants in Five Unrelated Cases of Proteasome-Associated Autoinflammatory Syndromes (PRAAS). Front. Immunol., 14. sourceExperimental — accuracy not yet measured
The Introduction describes the ubiquitin–proteasome system and identifies the 19S and 20S particles as components of the 26S proteasome. The Discussion links mutations in genes encoding those proteasome components to neurodevelopmental disorders. Page numbers are not available in our copy. (LLM, conf=0.88)
- Supportedcites [6] Cuinat, 2024, Understanding Neurodevelopmental Proteasomopathies as New Rare Disease Entities: A Review of Current Concepts, Molecular Biomarkers, and Perspectives, Genes Dis. sourceExperimental — accuracy not yet measured
The Genetics of proteasomopathies section identifies neurodevelopmental proteasomopathies as early-onset disorders caused by alterations in proteasome genes. The Introduction places the proteasome within the ubiquitin–proteasome system and describes the 26S proteasome. The UPS and 26S proteasome are not separate systems, but the claim’s underlying account is supported. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although its MIM phenotype number is not associated with a specific phenotype, it was previously associated with neurodevelopmental disorders [7].”
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > 1. Introduction
What the sources say
- Supportedcites [7] Küry, S., Stanton, J.E., van Woerden, G., Hsieh, T.-C., Rosenfelt, C., Scott-Boyer, M.P., Most, V., Wang, T., Papendorf, J.J., and de Konink, C. (2024). Unveiling the Crucial Neuronal Role of the Proteasomal ATPase Subunit Gene PSMC5 in Neurodevelopmental Proteasomopathies. medRxiv. source
The Discussion states that a connection between PSMC5 and neurodevelopmental disorders had already been strongly suggested by a large international cohort study. The paper also reports a neurodevelopmental phenotype in its own affected individuals, supporting the cited association. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As documented, the intracerebroventricular administration of shRNA PSMC5 in mice resulted in neuroprotective effects.”
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > 1. Introduction
What the sources say
- Supportedcites [11] Bi, 2023, PSMC5 Regulates Microglial Polarization and Activation in LPS-Induced Cognitive Deficits and Motor Impairments by Interacting with TLR4, J. Neuroinflamm. source
The mouse methods section describes intracerebroventricular administration of shRNA PSMC5. The results sections report improved cognitive and motor performance, healthier synaptic ultrastructure, and reduced neuroinflammation in LPS-treated mice after shRNA PSMC5 treatment. Page numbers are not provided in the supplied passages. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Specifically, the Pro320Arg mutation disrupts proteasome function by altering the interaction between the 19S regulatory particle and the 20S core particle, as demonstrated by in vitro assays [12].”
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > 3. Discussion
What the sources say
- Supportedcites [12] Yu, 2024, PSMC5 Insufficiency and P320R Mutation Impair Proteasome Function, Hum. Mol. Genet. source
The Results section reports that PSMC5 P320R reduced co-immunoprecipitation of 20S core-particle subunits with PSMC5 while leaving 19S subunit association unchanged. It also reports impaired proteasome activity in P320R-expressing cells, supporting the claimed link between altered 19S–20S association and proteasome dysfunction. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
31 more claims · 1 with their cited sources checked
Create a free account to see all 65 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 14
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > Abstract
“as well as on both of his unaffected parents.”
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > 2. Results > 2.1. Clinical Report
“The patient was a female second-born child”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > Abstract
“Keywords: 26S proteasome, the 20S regulatory subunit, ubiquitin proteasome system”
§ Strengthening the Role of PSMC5 as a Potential Gene Associated with Neurodevelopmental Disorders > 1. Introduction
“The 26S proteasome consists of a 20S catalytic core particle and one or two 19S regulatory particles that recognize and unfold ubiquitinated substrates [2,3].”
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594 · cited 1×
“The identified variant was classified using the “American College of Medical Genetics” (ACMG) guidelines and criteria [22].”
VarSome: the human genomic variant search engine
Kopanos, C., Tsiolkas, V., Kouris, A., Chapple, C. E., Albarca Aguilera, M., Meyer, R., & Massouras, A. (2019) · Bioinformatics · doi:10.1093/bioinformatics/bty897 · Cited by 1,883
Structure and Function of the 26S Proteasome
Bard, J. A. M., Goodall, E. A., Greene, E. R., Jonsson, E., Dong, K. C., & Martin, A. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-011931 · Cited by 819 · cited 1×
“It plays a critical role in maintaining cellular protein homeostasis by selectively removing misfolded, damaged, or regulatory proteins tagged with ubiquitin [1].”
Assembly, structure, and function of the 26S proteasome
Bedford, L., Paine, S., Sheppard, P. W., Mayer, R. J., & Roelofs, J. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.03.007 · Cited by 252 · cited 1×
“This tightly regulated degradation process is essential for numerous cellular functions, including protein homeostasis, DNA synthesis, transcription, translation, cell cycle control, signal transduction, and stress responses [4].”
Ouhaz, Z., Fleming, H., & Mitchell, A. S. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00033 · Cited by 142 · cited 1×
“This brain region has been consistently implicated in neurodevelopmental disorders and is known to play a critical role in cognitive function [13,14].”
Proteasome in action: substrate degradation by the 26S proteasome
Sahu, I., & Glickman, M. H. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200382 · Cited by 106 · cited 1×
“The 26S proteasome consists of a 20S catalytic core particle and one or two 19S regulatory particles that recognize and unfold ubiquitinated substrates [2,3].”
Thyroid Hormone Activates Fibroblast Growth Factor Receptor-1 in Bone
Stevens, D. A., Harvey, C. B., Scott, A. J., O’Shea, P. J., Barnard, J. C., Williams, A. J., Brady, G., Samarut, J., Chassande, O., & Williams, G. R. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0137 · Cited by 105
Thyroid Hormones Regulate Fibroblast Growth Factor Receptor Signaling during Chondrogenesis
Barnard, J. C., Williams, A. J., Rabier, B., Chassande, O., Samarut, J., Cheng, S.-Y., Bassett, J. H. D., & Williams, G. R. (2005) · Endocrinology · doi:10.1210/en.2005-0762 · Cited by 85 · cited 1×
“Although the thyroid hormone T3 modulates FGFR1 signaling [18–20], no explicit genotype-phenotype correlation links this variant to thyroid dysfunction.”
Ferguson, B. R., & Gao, W.-J. (2015) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.01027 · Cited by 75 · cited 1×
“This brain region has been consistently implicated in neurodevelopmental disorders and is known to play a critical role in cognitive function [13,14].”
Spliceosome Malfunction Causes Neurodevelopmental Disorders with Overlapping Features
Li, D., Wang, Q., Bayat, A., Battig, M. R., Zhou, Y., Bosch, D. G. M., van Haaften, G., Granger, L., Petersen, A. K., Pérez-Jurado, L. A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171235 · Cited by 46 · cited 1×
“Importantly, PRPF19 and other spliceosome components have been associated with neurodevelopmental disorders [16].”
Self-citationPapendorf, J. J., Ebstein, F., Alehashemi, S., Piotto, D. G. P., Kozlova, A., Terreri, M. T., Shcherbina, A., Rastegar, A., Rodrigues, M., Pereira, R., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190104 · Cited by 38 · cited 1×
“Among these, neurodevelopmental proteasomopathies have emerged as a complex group of syndromes caused by defects in genes related to key proteasome systems, such as the ubiquitin– proteasome system (UPS) and the previously mentioned 26S proteasome [5,6].”
Bi, W., Bao, K., Zhou, X., Deng, Y., Li, X., Zhang, J., Lan, X., Zhao, J., Lu, D., Xu, Y., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02904-9 · Cited by 36 · cited 1×
“In fact, PSMC5 was identified as a potential therapeutic target for the treatment of neurodegenerative diseases involving neuroinflammation-associated cognitive deficits and motor impairments induced by microglial activation [11].”
Assembly Mechanisms of Specialized Core Particles of the Proteasome
Bai, M., Zhao, X., Sahara, K., et al. (2014) · Biomolecules · doi:10.3390/biom4030662 · Cited by 32 · cited 1×
“The 26S proteasome consists of a 20S catalytic core particle and one or two 19S regulatory particles that recognize and unfold ubiquitinated substrates [2,3].”
Jang, E. R., Jang, H., Shi, P., Popa, G., Jeoung, M., & Galperin, E. (2015) · Journal of Cell Science · doi:10.1242/jcs.177543 · Cited by 27
O’Shea, P. J., Guigon, C. J., Williams, G. R., & Cheng, S.-Y. (2007) · Endocrinology · doi:10.1210/en.2007-0114 · Cited by 22 · cited 1×
“Although the thyroid hormone T3 modulates FGFR1 signaling [18–20], no explicit genotype-phenotype correlation links this variant to thyroid dysfunction.”
Mutations in Proteasome-Related Genes Are Associated with Thyroid Hemiagenesis
Budny, B., Szczepanek-Parulska, E., Zemojtel, T., Szaflarski, W., Rydzanicz, M., Wesoly, J., Handschuh, L., Wolinski, K., Piatek, K., Niedziela, M., et al. (2017) · Endocrine · doi:10.1007/s12020-017-1287-4 · Cited by 22 · cited 1×
“Nonetheless, variants in other genes encoding subunits of the 26S proteasome—such as PSMA1 , PSMA3 , PSMD3 , and PSMD2 —have been associated with thyroid dysfunction [17].”
Mouse Homologue of Yeast Prp19 Interacts with Mouse SUG1, the Regulatory Subunit of 26S Proteasome
Sihn, C.-R., Cho, S. Y., Lee, J. H., Lee, T. R., & Kim, S. H. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.134 · Cited by 21 · cited 1×
“The mutation is located at residue 320, within the 186–406 amino acid region of PSMC5, which has been described in mice as mediating the interaction with PRPF19 [15].”
Hoyle, J., Tan, K. H., & Fisher, E. M. C. (1997) · Human Genetics · doi:10.1007/s004390050356 · Cited by 19 · cited 2×
“This assumption is supported by previous findings indicating that the encoded protein subunit may be involved in transcriptional regulation, having been shown to interact with both the thyroid hormone receptor and retinoid X receptor-alpha [10].”
Cuinat, S., Bézieau, S., Deb, W., Mercier, S., Vignard, V., Isidor, B., Küry, S., & Ebstein, F. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2023.101130 · Cited by 10 · cited 1×
“Among these, neurodevelopmental proteasomopathies have emerged as a complex group of syndromes caused by defects in genes related to key proteasome systems, such as the ubiquitin– proteasome system (UPS) and the previously mentioned 26S proteasome [5,6].”
Küry, S., Stanton, J. E., van Woerden, G., Hsieh, T.-C., Rosenfelt, C., Scott-Boyer, M. P., Most, V., Wang, T., Papendorf, J. J., de Konink, C., et al. (2024) · doi:10.1101/2024.01.13.24301174 · Cited by 6 · cited 1×
“Although its MIM phenotype number is not associated with a specific phenotype, it was previously associated with neurodevelopmental disorders [7].”
Musumeci, A., Vinci, M., Treccarichi, S., Greco, D., Rizzo, B., Gloria, A., Federico, C., Saccone, S., Musumeci, S. A., & Calì, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094297 · Cited by 6 · cited 1×
“Genomic DNA was extracted from the peripheral blood leukocytes of the patient and both parents following a previously described procedure [21].”
Self-citationPSMC5 insufficiency and P320R mutation impair proteasome function
Yu, Z.-Q., Carmichael, J., Collins, G. A., D'Agostino, M. D., Lessard, M., Firth, H. V., Harijan, P., Fry, A. E., Dean, J., Zhang, J., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae085 · Cited by 4 · cited 3×
“Specifically, the Pro320Arg mutation disrupts proteasome function by altering the interaction between the 19S regulatory particle and the 20S core particle, as demonstrated by in vitro assays [12].”
InfluentialGalperin, E., Jang, E. R., Anderson, D., & Jang, H. (2017) · The FASEB Journal · doi:10.1096/fasebj.31.1_supplement.930.1 · Cited by 1 · cited 1×
“PSMC5 is an ATPase that belongs to the AAAs (ATPases associated with diverse cellular activities) family, known for its nonproteolytic chaperone-like functions [8,9].”
Cited by
Vinci, M., Treccarichi, S., Failla, P., Musumeci, A., Gloria, A., Virgillito, M., Federico, C., Saccone, S., & Calì, F. (2025) · Gene · doi:10.1016/j.gene.2025.149876 · Cited by 6
Self-citationCalı̀, F., Virgillito, M., Treccarichi, S., Musumeci, A., Failla, P., Papa, C., Rando, R. G., Federico, C., Saccone, S., & Vinci, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157586 · Cited by 3
“Genomic DNA was obtained from peripheral blood leukocytes of the patient and both parents, according to a previously described method [21].”
Self-citation
Metadata
- Authors
- Vinci, M., Musumeci, A., Papa, C., Ragalmuto, A., Saccone, S., Federico, C., Greco, D., Greco, V., Calì, F., & Treccarichi, S.
- Affiliations
- I.R.C.C.S. Oasi Maria SS (IT)
- University of Catania (IT)
- Oasi Research Institute-IRCCS, 94018 Troina, Italy
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-07-02
- Volume
- 26
- Issue
- 13
- Pages
- 6386
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12249637
- OpenAlex
- W4411973343
- Cited by
- 2
- References
- 26
- Citations by year
- 2025: 2
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Italian Ministry of Health “Ricerca Corrente 2017–2023”
- 5xmille
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- 26S proteasome, de novo mutations, intellectual disability, developmental delay, neurodevelopmental disorders, variants of uncertain significance, autosomal dominant inheritance, protein structure prediction, AlphaFold3, pathogenicity prediction
- MeSH terms
- Exome Sequencing, Humans, Intellectual Disability, Mutation, Pedigree, Genetic Predisposition to Disease, Proteasome Endopeptidase Complex, Neurodevelopmental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.